Form 4: Enliven Therapeutics CEO Samuel Kintz Sells 5,000 Shares
SEC Filing
Enliven Therapeutics CEO Samuel Kintz sold 5,000 shares of common stock at an average price of $16.4192, according to a Form 4 filing.
Summary
- On April 17, 2025, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 5,000 shares of common stock.
- The sale was executed at a weighted average price of $16.4192 per share, with individual trades ranging from $16.09 to $16.68.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
- Following the transaction, Kintz indirectly owns 985,392 shares through The Kintz & Egan Trust Dated March 30, 2019, where he serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a routine disclosure of a stock sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to sell shares under pre-arranged trading plans to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large.
Key Dates
| Date | Description |
|---|---|
| March 30, 2019 | Date of The Kintz & Egan Trust |
| November 15, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| April 17, 2025 | Date of stock sale |
| April 21, 2025 | Date of Form 4 filing |
Keywords
Enliven Therapeutics, Samuel Kintz, Form 4, Stock Sale, ELVN, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.